COVID-19. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: Receiving 10 cc of curcuma herbal composition every 6 hours between meals asynchronously with other drugs for 10-14 days. This medicine will be produced in closed a
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Affected individuals identified by a specific corona diagnosis test Having a conscious consent form signed to participate in the study Failure to participate simultaneously in another clinical trial
Exclusion criteria
Exclusion criteria: People with suspicious and probable symptoms of the disease pregnant women Breastfeeding women Liver or kidney failure based on individual or family statements Candidates admitted at the beginning of the study Immune deficiency (treated with corticosteroids over 12.5 mg / d, prednisolone over two weeks, chemotherapy, malignancies, organ transplants, HIV patients, other viral diseases) Coagulation disorders and the use of anticoagulants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization rate. Timepoint: After the intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease.;Mortality rate. Timepoint: After the intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease. | — |
Secondary
| Measure | Time frame |
|---|---|
| The drug side effects rate. Timepoint: After intervention. Method of measurement: Side effects checklist.;Serum levels of ESR, CBC, LDH, SGPT, SGOT and BUN, Cr. Timepoint: Before and after the intervention. Method of measurement: Using biochemical methods in the autoanalyzer.;Rate of symptoms (dry cough, chills, sore throat, shortness of breath / difficulty breathing, temperature equal to 37.8, anorexia, gastrointestinal symptoms, loss of sense of smell and taste, ...). Timepoint: During the intervention , 3 and 30 day after intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease.;Number of hospitalization days in hospitalized individuals. Timepoint: During the intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease.;ICU admission rate in hospitalized individuals. Timepoint: During the intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease.;Rate of need for ventilation in hospitalized people. Timepoint: During the intervention. Method of measurement: Questionnaire of clinical and paraclinical symptoms of the disease.;Satisfaction rate of the drug. Timepoint: During the intervention. Method of measurement: Checklist of side effects and drug satisfaction. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Mirzaei
Tabriz University of Medical Sciences
Outcome results
None listed